Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Cytokinetics Inc’s stock clocked out at $39.48, up 0.84% from its previous closing price of $39.15. In other words, the price has increased by $0.84 from its previous closing price. On the day, 1.08 million shares were traded. CYTK stock price reached its highest trading level at $39.53 during the session, while it also had its lowest trading level at $38.41.
Ratios:
To gain a deeper understanding of CYTK’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.17 and its Current Ratio is at 6.17.
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on February 07, 2025, initiated with a Buy rating and assigned the stock a target price of $86.
On January 22, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $80.
On November 08, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $80.RBC Capital Mkts initiated its Outperform rating on November 08, 2024, with a $80 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 15 ’25 when HENDERSON JOHN T sold 3,190 shares for $38.66 per share. The transaction valued at 123,325 led to the insider holds 66,348 shares of the business.
JOHN T. HENDERSON bought 3,190 shares of CYTK for $126,994 on Apr 15 ’25. On Apr 10 ’25, another insider, Blum Robert I, who serves as the President & CEO of the company, sold 5,000 shares for $36.77 each. As a result, the insider received 183,850 and left with 422,629 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 4705542144 and an Enterprise Value of 4522020864. For the stock, the TTM Price-to-Sale (P/S) ratio is 254.77. Its current Enterprise Value per Revenue stands at 244.778 whereas that against EBITDA is -8.585.
Stock Price History:
The Beta on a monthly basis for CYTK is 0.82, which has changed by -0.41554403 over the last 52 weeks, in comparison to a change of 0.0635103 over the same period for the S&P500. Over the past 52 weeks, CYTK has reached a high of $69.90, while it has fallen to a 52-week low of $32.74. The 50-Day Moving Average of the stock is -8.05%, while the 200-Day Moving Average is calculated to be -21.75%.
Shares Statistics:
It appears that CYTK traded 1.97M shares on average per day over the past three months and 2685230 shares per day over the past ten days. A total of 118.21M shares are outstanding, with a floating share count of 116.06M. Insiders hold about 2.62% of the company’s shares, while institutions hold 109.38% stake in the company. Shares short for CYTK as of 1743379200 were 14333413 with a Short Ratio of 7.28, compared to 1740700800 on 14072458. Therefore, it implies a Short% of Shares Outstanding of 14333413 and a Short% of Float of 18.43.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
